PULSE BIOSCIENCES, INC.
About PULSE BIOSCIENCES, INC.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $350.0K
- Net income
- -$72.8M
- Total assets
- $94.5M
- Market cap
- $1.8B
- Gross margin
- -54.0%
- Operating margin
- -21982.6%
- Net margin
- -20794.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $350.0K
- Cost of revenue
- $539.0K
- Gross profit
- -$189.0K
- Operating expenses
- $76.8M
- Operating income
- -$76.9M
- Income tax
- $0
- Net income
- -$72.8M
- EPS (basic)
- $-1.08
Balance sheet
- Total assets
- $94.5M
- Current assets
- $83.4M
- Total liabilities
- $13.9M
- Current liabilities
- $7.9M
- Shareholders’ equity
- $80.7M
Cash flow
- Operating cash flow
- -$54.1M
- Investing cash flow
- -$335.0K
- Financing cash flow
- $17.2M
- Net cash flow
- -$37.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.8B
- Shares outstanding
- 70.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 18, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $72.8M in FY2025.
- Revenue declined 75% from FY2021 to FY2025.
- Gross margin of -54.0%, net margin -20794.6%.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PULSE BIOSCIENCES, INC..
Write a review
News about PULSE BIOSCIENCES, INC.
News & sentiment via Polygon.io
